Form 4: Upstream Bio Director Liam Ratcliffe Granted Stock Options

Upstream Bio, Inc. Director Liam Ratcliffe was granted 17,096 stock options with an exercise price of $11.59, vesting over time and subject to continued service.

Summary

• Liam Ratcliffe, a Director of Upstream Bio, Inc. (UPB), was granted 17,096 stock options.
• The transaction date for this grant was June 10, 2025.
• The exercise price for these stock options is $11.59 per share.
• The options are set to vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders of the Issuer, contingent on Mr. Ratcliffe's continued service.
• The expiration date for these stock options is June 9, 2035.
• The filing also includes a Substitute Power of Attorney, dated December 19, 2024, appointing Allison Ambrose as a substitute attorney-in-fact for several individuals, including Liam Ratcliffe, to execute SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event (expected), which aligns director interests with shareholders, but does not indicate new operational or financial performance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of equity compensation for directors, indicating routine corporate governance practices.

Negatives

• No direct negative implications are apparent from this routine stock option grant.

Risks

• The vesting of the stock options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before vesting conditions are met.
• The value of the options is dependent on the future market price of Upstream Bio's common stock exceeding the exercise price of $11.59.

Future Outlook

The stock options granted to Director Liam Ratcliffe are subject to future vesting conditions, specifically on the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, provided his continued service to the company.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule tied to continued service and a specific future date or corporate event (Annual Meeting) is typical for such equity awards, comparable to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Liam Ratcliffe, a director of Upstream Bio, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: While not directly impacted, the compensation structure for directors can reflect broader company compensation philosophies.

Next Steps

• The granted stock options will vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, subject to Liam Ratcliffe's continued service.
• Following vesting, Liam Ratcliffe will have the right to exercise these options to acquire common stock of Upstream Bio, Inc. at the specified exercise price.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Liam Ratcliffe, Corporate Governance